ALLMedicine™ Systemic Mastocytosis Center
Research & Reviews 402 results
https://doi.org/10.1016/j.jaci.2021.12.786
The Journal of Allergy and Clinical Immunology; Hermans MAW, Heeringa JJ et. al.
Jan 14th, 2022 - Indolent systemic mastocytosis (ISM) is characterized by pathological accumulation of mast cells. The mechanism behind its phenotypic heterogeneity is not well understood. Interaction of mast cells with other immune cells might cause systemic infl...
https://clinicaltrials.gov/ct2/show/NCT00001756
Jan 12th, 2022 - The purpose of this protocol is to obtain large numbers of CD34+ cells from the peripheral blood of healthy volunteers and patients with systemic mastocytosis or other related allergic, hematological, and immunological conditions by leukapheresis ...
https://clinicaltrials.gov/ct2/show/NCT04910685
Dec 22nd, 2021 - This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of BLU-263 + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms are not adequ...
https://doi.org/10.1186/s13256-021-03190-w 10.1016/S1081-1206(10)63560-0 10.1016/j.jaci.2017.06.007 10.1016/j.iac.2018.04.002 10.1503/cmaj.111031 10.1016/j.toxicon.2010.02.006 10.1016/S0091-6749(97)70263-X 10.1007/s11606-012-1996-6 10.1016/j.jaci.2007.07.033 10.1016/j.jaci.2015.03.048 10.1503/cmaj.080612 10.1016/j.jaci.2019.08.023 10.1016/j.jaip.2018.11.045 10.1016/j.jaci.2017.04.010 10.1056/NEJMra1409760 10.1016/j.jaip.2013.06.003 10.1016/B978-0-12-386037-8.00006-5 10.1002/eji.201040559
Journal of Medical Case Reports; Brock I, Eng N et. al.
Dec 19th, 2021 - Mast cells are closely associated with epithelium, serving as sentinels responsible for the recognition of tissue injury and coordination of the initial inflammatory response. Upon detection of the injured cell content, mast cells then tailor the ...
https://clinicaltrials.gov/ct2/show/NCT04996875
Dec 16th, 2021 - This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast ...
Guidelines 1 results
https://doi.org/10.6004/jnccn.2018.0088
Journal of the National Comprehensive Cancer Network : JN... Gotlib J, Gerds AT et. al.
Dec 14th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt...
Drugs 179 results see all →
Clinicaltrials.gov 16 results
https://clinicaltrials.gov/ct2/show/NCT00001756
Jan 12th, 2022 - The purpose of this protocol is to obtain large numbers of CD34+ cells from the peripheral blood of healthy volunteers and patients with systemic mastocytosis or other related allergic, hematological, and immunological conditions by leukapheresis ...
https://clinicaltrials.gov/ct2/show/NCT04910685
Dec 22nd, 2021 - This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of BLU-263 + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms are not adequ...
https://clinicaltrials.gov/ct2/show/NCT04996875
Dec 16th, 2021 - This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast ...
https://clinicaltrials.gov/ct2/show/NCT04333108
Nov 30th, 2021 - Masitinib is a selective tyrosine kinase inhibitor that modulates mast cell activity via inhibition of c-Kit, Lyn and Fyn kinase signaling pathways. This is a multicenter, randomized, double-blind, placebo-controlled, 2-parallel-group, trial compa...
https://clinicaltrials.gov/ct2/show/NCT03731260
Oct 26th, 2021 - This is a Phase 2, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of avapritinib + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms are not ade...
News 43 results
https://www.medscape.com/viewarticle/962196
Nov 3rd, 2021 - A number of late-phase clinical trials in leukemia have opened in recent months. Maybe one of your patients could benefit from being enrolled. Adults and Children With Acute or Chronic Leukemias A phase 2 study partnering with the National Marrow ...
https://www.medscape.com/viewarticle/957272
Aug 26th, 2021 - The National Institute for Health and Care Excellence (NICE) has published new draft guidance recommending midostaurin (Rydapt, Novartis) as a treatment for advanced systemic mastocytosis in adults. There are three diverse subtypes of the rare hae...
https://www.onclive.com/view/well-differentiated-systemic-mastocytosis-vs-chronic-mast-cell-leukemia
Aug 19th, 2021 - Dan DeAngelo, MD, PhD: That’s a phenomenal presentation of a very a rare disease. Now, we’re talking about hen’s teeth in a rare disease. I have seen a lot of mast cells, but I have only seen 2 cases of well-differentiated systemic mastocytosis [W...
https://www.onclive.com/view/case-4-a-68-year-old-female-with-mast-cell-leukemia
Aug 19th, 2021 - Sa Wang, MD: I’ll show a couple of cases. I don’t have very detailed treatment information, but I think I have 3 cases. I’ll show some variety in a different diagnostic entity within this category of SM [systemic mastocytosis]. This is a 68-year-o...
https://www.onclive.com/view/case-3-indolent-systemic-mastocytosis
Aug 19th, 2021 - Dan DeAngelo, MD, PhD: I think the next case will be right up your alley, Dr. Lugar, in terms of highlighting a case that was a challenge. This is a patient of mine who presented with urticaria pigmentosa, 15 years ago now, 2006; and more prominen...
